AUR-AF98-TTM1-A-1-1-R-A742-41
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E7-A7DV-01A-11R-A33J-07 | — | — | 0.878 |
| 2 | SRR6013500 | — | cohortA1 | 0.875 |
| 3 | A2170829-B80C-49F2-8FB6-39B8ACFB27CB | — | — | 0.872 |
| 4 | 27875588-7C41-49BB-A4C0-A66D72A12499 | — | — | 0.871 |
| 5 | SRR6013499 | — | cohortA1 | 0.871 |
| 6 | F2EB65DD-59F7-4C1F-8D92-0DCF439FF41A | — | — | 0.870 |
| 7 | SRR8518316 | — | D | 0.870 |
| 8 | TCGA-A2-A0SV-01A-11R-A084-07 | — | C | 0.869 |
| 9 | BS_JG9JZTA9 | low-grade glioma | — | 0.861 |
| 10 | DB8DD33B-34B6-4F4B-AD87-D666899A26BC | — | — | 0.860 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.560 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.520 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.500 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.490 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.470 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.470 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.430 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.430 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| COMPLEMENT | 0.380 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.350 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.340 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.270 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |